Lawsuit Notification: The Gross Law Firm has issued a notice to DexCom shareholders, encouraging those who purchased DXCM shares between January 8, 2024, and September 17, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
Design Flaw Allegations: The lawsuit alleges that DexCom made significant design changes to its G6 and G7 glucose monitoring products without FDA authorization, resulting in decreased reliability and posing health risks to users relying on accurate readings.
Increased Regulatory Risks: Due to these issues, DexCom is subjected to heightened regulatory scrutiny and enforcement risks, which could lead to significant legal, reputational, and financial harm, adversely affecting the company's future market performance.
Shareholder Action Deadline: The deadline for shareholders to register for participation in the class action lawsuit is December 26, 2025, and failure to register in time may result in the loss of recovery opportunities, impacting investor rights.
DXCM
$66.37+Infinity%1D
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 85.75 USD with a low forecast of 63.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 85.75 USD with a low forecast of 63.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 65.730
Low
63.00
Averages
85.75
High
112.00
Current: 65.730
Low
63.00
Averages
85.75
High
112.00
Citi
Buy
maintain
$75 -> $77
2025-12-11
New
Reason
Citi
Price Target
$75 -> $77
2025-12-11
New
maintain
Buy
Reason
Citi raised the firm's price target on DexCom to $77 from $75 and keeps a Buy rating on the shares. Citi also opened an "upside 90-day catalyst watch" on DexCom. The firm sees the stock moving higher on the company's 2026 guidance in January.
Morgan Stanley
Patrick Wood
Equal Weight
to
Overweight
upgrade
$75
2025-12-02
Reason
Morgan Stanley
Patrick Wood
Price Target
$75
2025-12-02
upgrade
Equal Weight
to
Overweight
Reason
Morgan Stanley analyst Patrick Wood upgraded DexCom to Overweight from Equal Weight with a $75 price target.
Morgan Stanley
Morgan Stanley
Equal Weight -> Overweight
upgrade
$63 -> $75
2025-12-02
Reason
Morgan Stanley
Morgan Stanley
Price Target
$63 -> $75
2025-12-02
upgrade
Equal Weight -> Overweight
Reason
As previously reported, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, up from $63, citing signs that the company is already turning the corner from a number of operational challenges while valuation remains at trough levels. The firm expects this turn to become apparent in the full results due in January or February, adding that it believes the G7 15-day rollout's impact on margins in the year ahead is "underappreciated" and it expects the stock to re-rate as catalysts play out.
BofA
analyst
Buy
maintain
$10
2025-11-25
Reason
BofA
analyst
Price Target
$10
2025-11-25
maintain
Buy
Reason
After the Office of Inspector General report on Medicare payments for continuous glucose monitors and supplies came out, BofA noted that the report is just the OIG's recommendation to CMS and is not an update to the CMS proposal regarding competitive bidding from July. With that said, the firm views the OIG report positively for DexCom as it shows Class 2 supplies are priced fairly to in line with Medicare expectations, adds the analyst, who maintains a Buy rating and $10 price target on the shares.
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
